Last reviewed · How we verify

Metformin 1500mg, QD — Competitive Intelligence Brief

Metformin 1500mg, QD (Metformin 1500mg, QD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial complex I Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin 1500mg, QD (Metformin 1500mg, QD) — Daewoong Pharmaceutical Co. LTD.. Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metformin 1500mg, QD TARGET Metformin 1500mg, QD Daewoong Pharmaceutical Co. LTD. phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial complex I
Metformin + Clomiphene Metformin + Clomiphene University of Auckland, New Zealand marketed Combination therapy: biguanide + selective estrogen receptor modulator (SERM) Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)
Liraglutide and metformin Liraglutide and metformin Peking University Third Hospital marketed GLP-1 receptor agonist + biguanide combination GLP-1 receptor; metformin complex I inhibitor
metformin and rosiglitazone metformin and rosiglitazone New York Medical College marketed Antidiabetic combination (biguanide + thiazolidinedione) AMPK (metformin); PPAR-γ (rosiglitazone)
Mandated back ground therapy Mandated back ground therapy Sanofi marketed biguanide
GLIMEPIRIDE + METFORMIN GLIMEPIRIDE + METFORMIN Sanofi marketed Sulfonylurea + biguanide combination ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Metformin / Placebo treatment for 4 months Metformin / Placebo treatment for 4 months Norwegian University of Science and Technology marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin 1500mg, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-1500mg-qd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: